Although induction of vasculitis has never been reported in patients for the two oral PDE4 inhibitors roflumilast and apremilast, which have been on the market for many years, there is still some concern on this potentially serious side effect for the introduction of new PDE4 inhibitors. Here, PDE4A is linked to vasculitis.